Advances in genomics and molecular profiling have helped better define subtypes of TNBC with distinct biologic drivers to guide the therapeutic development of targeted therapies, including vascular endothelial growth factor A (VEGF-A), a major pro-angiogenic growth factor [1], immune checkpoint inhibitors for programmed cell death ligand 1 (PD-L1)-positive TNBC [2] and poly (ADP-ribose) polymerase (PARP) inhibitors for breast cancer 1/2 (BRCA1/2) mutant TNBC [3,4]. This evidence concerns the gene VEGFA and breast carcinoma.